Bio Farma taps Artes for VLP technology

Germany-based Artes Biotechnology has teamed up with Indonesian vaccine maker Bio Farma to expand use of its virus-like particle (VLP) technology. Bio Farma will use Artes' Metavax VLP technology, a vaccine approach based on modifications to duck hepatitis B virus. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.